Microbiota Modulation in Patients with Metabolic Syndrome

Autores da FMUP

• Rui Manuel Moreira Araújo

  Autor

• Pedro Filipe Vieira Pimentel Nunes

  Autor

Participantes de fora da FMUP

• Canha, M.

Unidades de investigação

• Cirurgia e Fisiologia

• Neurociências Clínicas e Saúde Mental

Abstract

Metabolic syndrome (MS) comprises a vast range of metabolic dysfunctions, which can be associated to cardiovascular disease risk factors. MS is reaching pandemic levels worldwide and it currently affects around 25% in the adult population of developed countries. The definition states for the diagnosis of MS may be clear, but it is also relevant to interpret the patient data and realize whether similar criteria were used by different clinicians. The different criteria explain, at least in part, the controversies on the theme. Several studies are presently focusing on the microbiota changes according to the components of MS. It is widely accepted that the gut microbiota is a regulator of metabolic homeostasis, being the gut microbiome in MS described as dysbiotic and certain taxonomic groups associated to metabolic changes. Probiotics, and more recently synbiotics, arise as promising therapeutic alternatives that can mitigate some metabolic disturbances, namely by correcting the microbiome and bringing homeostasis to the gut. The most recent studies were revised and the promising results and perspectives revealed in this review.

Keywords

• inflammation; gut metabolites; gut microbiome; metabolic syndrome; obesity; probiotics; synbiotics